Zimelidine

Zimelidine

File:Zimelidine.svg

Chemical structure of Zimelidine

Zimelidine is a selective serotonin reuptake inhibitor (SSRI) that was developed in the late 1970s as an antidepressant. It was the first SSRI to be marketed, but it was later withdrawn due to concerns about its side effects.

History

Zimelidine was developed by the Swedish company Astra AB in the late 1970s. It was introduced to the market in 1982 as an antidepressant. However, it was withdrawn in 1983 after reports of serious side effects, including Guillain–Barré syndrome.

Mechanism of Action

Zimelidine works by inhibiting the reuptake of serotonin in the brain, which increases the levels of serotonin available to bind to serotonin receptors. This action is thought to contribute to its antidepressant effects.

Side Effects

The use of Zimelidine was associated with several side effects, some of which were severe. Common side effects included nausea, dry mouth, and dizziness. More serious side effects included allergic reactions and neurological disorders such as Guillain–Barré syndrome.

Withdrawal

Due to the risk of serious side effects, Zimelidine was withdrawn from the market in 1983. The withdrawal highlighted the importance of post-marketing surveillance in the detection of adverse drug reactions.

Legacy

Despite its withdrawal, Zimelidine paved the way for the development of other SSRIs, which have become some of the most commonly prescribed antidepressants. The development of Zimelidine marked a significant advancement in the treatment of depression, as it was the first drug to specifically target serotonin reuptake.

Related pages

• Selective serotonin reuptake inhibitor
• Antidepressant
• Guillain–Barré syndrome
• Serotonin